https://aseestant.ceon.rs/index.php/jomb/issue/feedJournal of Medical Biochemistry2025-11-19T04:10:45+01:00Snežana Jovičićjmedbio.managing.editor@gmail.comSCIndeks Assistanthttps://aseestant.ceon.rs/index.php/jomb/article/view/57277Analysis of Factors Influencing Weight Regain after Bariatric-Metabolic Surgery in Obesity Hypoventilation Syndrome Patients Based on Gastrointestinal Peptide Hormones2025-11-02T16:18:06+01:00Jingjing Zhangzhangjingjing859@163.comShadike Apaersadikjan88@163.comShuo Zhang17590083026@163.comGuanyou Lianglgy08081059@163.comTao Lidoctorli666@163.comXinling Caocaoxinling0101@163.com<p class="MsoNormal"><strong><span style="font-family: 'Times New Roman'; font-size: 12pt;">Background: </span></strong><span style="mso-spacerun: 'yes'; font-family: 'Times New Roman'; mso-fareast-font-family: 宋体; font-size: 12.0000pt; mso-font-kerning: 1.0000pt;">Obesity is becoming increasingly prevalent in modern society, leading to a rise in the incidence of obesity hypoventilation syndrome (OHS). This study analyzes the factors influencing weight regain in OHS patients following </span><span style="mso-spacerun: 'yes'; font-family: 宋体; mso-ascii-font-family: 'Times New Roman'; mso-hansi-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; font-size: 12.0000pt; mso-font-kerning: 1.0000pt;"><span style="font-family: Times New Roman;">l</span></span><span style="mso-spacerun: 'yes'; font-family: 'Times New Roman'; mso-fareast-font-family: 宋体; font-size: 12.0000pt; mso-font-kerning: 1.0000pt;">aparoscopic sleeve gastrectomy (LSG), based on gastrointestinal peptide hormones.</span></p> <p class="MsoNormal"><strong><span style="font-family: 'Times New Roman'; font-size: 12pt;">Methods:</span></strong><span style="mso-spacerun: 'yes'; font-family: 'Times New Roman'; mso-fareast-font-family: 宋体; font-size: 12.0000pt; mso-font-kerning: 1.0000pt;"> A total of 134 OHS patients who underwent LSG at our hospital between January 2023 and January 2024 were enrolled. The alterations in gastrointestinal peptide hormones, including insulin (INS), leptin (Lep), glucagon-like peptide-1 (GLP-1), and ghrelin (GHR), before and after surgery were measured. Subsequently, a 6-month follow-up was conducted. Patients with weight regain were identified, and the predictive value of gastrointestinal peptide hormones for weight regain was analyzed. Logistic regression was then employed to analyze the related factors affecting weight regain.</span></p> <p class="MsoNormal"><strong><span style="font-family: 'Times New Roman'; font-size: 12pt;">Results:</span></strong><span style="mso-spacerun: 'yes'; font-family: 'Times New Roman'; mso-fareast-font-family: 宋体; font-size: 12.0000pt; mso-font-kerning: 1.0000pt;"> Following the surgical procedure, a significant increase was observed in the levels of INS, Lep, and GLP, accompanied by a notable decrease in GHR levels among the patients (P < 0.05). During the follow-up period, 32 patients experienced weight regain. The receiver operating characteristic (ROC) curve analysis demonstrated that gastrointestinal peptide hormones exhibited outstanding predictive capabilities for postoperative weight regain. Moreover, through statistical analysis, it was determined that unfavorable dietary habits, lack of regular exercise, trace element deficiencies, and negative emotional states were independent risk factors influencing weight regain following LSG (P < 0.05).</span></p> <p class="MsoNormal"><strong><span style="font-family: 'Times New Roman'; font-size: 12pt;">Conclusion:</span></strong><span style="mso-spacerun: 'yes'; font-family: 'Times New Roman'; mso-fareast-font-family: 宋体; font-size: 12.0000pt; mso-font-kerning: 1.0000pt;"> There is a close correlation between gastrointestinal peptide hormones and post-LSG weight alterations in patients with OHS.</span></p>2025-05-06T00:00:00+02:00Copyright (c) 2025 Jingjing Zhang, Shadike Apaer, Shuo Zhang, Guanyou Liang, Tao Li, Xinling Caohttps://aseestant.ceon.rs/index.php/jomb/article/view/57755Traditional Chinese Medicine Constitution Types and Apolipoprotein B in Hyperuricemia: Associations with Cardiovascular Risk2025-11-02T15:27:04+01:00Shuo Yang35396239@qq.comJinfeng Lilijinfeng@gzucm.edu.cnHongli Zengzenghongli2022@163.comXueping Zhangzxpfire@126.comDeliang Xiong15945203@qq.comWenyi Tangtwy1057700531@163.comBin Sunbengerrard@sina.comPeng Yu844503128@qq.comXiaohong Hewdtsxh521@126.comWeizheng Zhang13822100512@163.com<p style="line-height: 150%; mso-pagination: widow-orphan;"><strong><span lang="EN-US" style="font-family: 'Times New Roman',serif;">Background: </span></strong><span lang="EN-US" style="font-family: 'Times New Roman',serif;">To explore the correlation between different traditional Chinese medicine (TCM) constitution types and apolipoprotein B (ApoB) in patients with <a name="_Hlk177238532"></a>hyperuricemia (HUA), and to investigate the relationships between TCM constitutions, uric acid levels, and various cardiovascular risk factors.</span></p> <p class="MsoNormal" style="line-height: 150%; mso-pagination: widow-orphan;"><strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif;">Methods: </span></strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif;">A cross-sectional study involving 683 patients diagnosed with HUA was conducted. Patients' TCM constitutions were classified using the standardized "Classification and Determination of TCM Constitution" questionnaire. Serum uric acid (UA), lipid profiles, ApoB, and homocysteine (Hcy) levels were measured. </span></p> <p class="MsoNormal" style="line-height: 150%; mso-pagination: widow-orphan;"><strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif;">Results:</span></strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif;"> Among 683 HUA patients, phlegm-dampness (22.99%) and damp-heat constitution (20.06%) were the most common TCM constitution types. UA, ApoB, and Hcy levels in patients with phlegm-damp constitution were significantly higher than those in other constitutions (P<0.05). UA levels were negatively correlated with HDL-C (r=-0.472, P=0.027) and positively correlated with ApoB (r=0.618, P=0.012), and Hcy (r=0.492, P=0.018). Male gender, BMI, ApoB, Hcy, and phlegm-dampness constitution are independent factors associated with UA levels. Patients with high ApoB levels had a significantly higher incidence of cardiovascular diseases compared to those with low ApoB levels (male: 42.73% vs 22.81%, P<0.001; female: 37.82% vs 25.21%, P=0.036). Logistic regression analysis revealed that phlegm-dampness constitution (OR=2.18, 95% CI: 1.42-3.35, P<0.001) and damp-heat constitution (OR=1.86, 95% CI: 1.21-2.87, P=0.005) were independently associated with increased risk of cardiovascular diseases.</span></p> <p class="MsoNormal" style="line-height: 150%; mso-pagination: widow-orphan;"><strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif;">Conclusion: </span></strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif;">Phlegm-damp and damp-heat constitutions are the most common TCM constitution types in HUA patients and are associated with higher levels of UA, ApoB, and Hcy. These constitution types are independently associated with increased cardiovascular risk.</span></p>2025-05-06T00:00:00+02:00Copyright (c) 2025 Shuo Yang, Jinfeng Li, Hongli Zeng, Xueping Zhang, Deliang Xiong, Wenyi Tang, Bin Sun, Peng Yu, Xiaohong He, Weizheng Zhanghttps://aseestant.ceon.rs/index.php/jomb/article/view/58279THE ROLE OF MICRORNA-346 IN PROSTATE CANCER PROGRESSION: CLINICAL SIGNIFICANCE AND BIOMARKER POTENTIAL2025-11-02T16:21:36+01:00Lei Wangwakuyi2005@126.comYanqing Wangyanqingwang01@163.comLi Tian15224469162@163.comZhengwei Wangwangzhengweizhuren@126.comXiaoqiang Liuxiaoqiangliu03@163.comGuangzhou Chenchengguangzhou1@126.com<p class="MsoNormal" style="text-autospace: ideograph-numeric; mso-pagination: none; text-align: justify; text-justify: inter-ideograph;" align="justify"><strong><span style="font-family: 'Times New Roman'; font-size: 12pt;">Objective: </span></strong><span style="font-family: 'Times New Roman'; font-size: 12pt;">The aim of this study was to analyze the expression changes and clinical significance of microRNA-346 (MiRNA-346) in PCa genesis, development and hormone resistance transformation.</span></p> <p class="MsoNormal" style="text-autospace: ideograph-numeric; mso-pagination: none; text-align: justify; text-justify: inter-ideograph;" align="justify"><strong><span style="font-family: 'Times New Roman'; font-size: 12pt;">Method</span></strong><strong><span style="font-family: 'Times New Roman'; font-size: 12pt;">: </span></strong><span style="font-family: 'Times New Roman'; font-size: 12pt;">Data of the middle-aged and elderly male patients who were treated in Tengzhou Central People’s Hospital from January 2017 to December 2023 were collected. The tissues and corresponding preoperative serum of 128 patients with newly diagnosed PCa and 130 patients with benign prostatic hyperplasia (BPH), 120 patients with hormone-sensitive PCa (HSPC), 116 patients with castration-resistant PCa (CRPC), and 150 healthy males of the same age who underwent physical examination in the physical examination center of our hospital were collected. Quantitative real-time polymerase chain reaction was used to detect the relative expression of miRNA-346 in the tissues and serum of the subjects. GraphPad Prism statistical analysis software was utilized to analyze the expression changes of miRNA-346 in the occurrence and progression of PCa and its correlation with clinical and pathological features.</span></p> <p class="MsoNormal" style="text-autospace: ideograph-numeric; mso-pagination: none; text-align: justify; text-justify: inter-ideograph;" align="justify"><strong><span style="font-family: 'Times New Roman'; font-size: 12pt;">Result</span></strong><strong><span style="font-family: 'Times New Roman'; font-size: 12pt;">: </span></strong><span style="font-family: 'Times New Roman'; font-size: 12pt;">The expression of miRNA-346 was significantly lower in PCa patients than in BPH patients and healthy population (P<0.001), while there was no difference between BPH and healthy population (P=0.516). Tissue and serum expression were positively correlated (P<0.001). miRNA-346 was negatively correlated with tPSA, PHI, clinical stage, and Gleason score in PCa tissue/serum (P<0.001). Serum miRNA-346 in CRPC patients was negatively correlated with time to transformation (r=0.6575) and survival (r=0.5699) (P<0.001). Serum miRNA-346 was positively correlated with tPSA and ALP in HSPC and CRPC patients (P<0.001).</span></p> <p class="MsoNormal" style="text-autospace: ideograph-numeric; mso-pagination: none; text-align: justify; text-justify: inter-ideograph;" align="justify"><strong><span style="font-family: 'Times New Roman'; font-size: 12pt;">Conclusion: </span></strong><span style="font-family: 'Times New Roman'; font-size: 12pt;">Serum miRNA-346 expression in the process of hormone resistance conversion in PCa is gradually increasing, making it a potential biomarker for monitoring PCa progression.</span></p>2025-05-09T00:00:00+02:00Copyright (c) 2025 Lei Wang, Yanqing Wang, Li Tian, Zhengwei Wang, Xiaoqiang Liu, Guangzhou Chenhttps://aseestant.ceon.rs/index.php/jomb/article/view/57295Non-invasive prenatal tests for chromosomal abnormality screening in in vitro fertilization elderly pregnant women in northwest China2025-11-02T15:27:05+01:00Shuyuan Xuexueshuyuan@stumail.nwu.edu.cnLixia Wangwlx-315@163.comZhen Yuyuzhen426@126.comJingying Zhuzhujyds@163.comLe FengFL210002@163.comGuifeng Ding3853775127@qq.comPenggao Daidaipg@nwu.edu.cn<p class="MsoNormal"><strong style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="mso-bidi-font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: 'Times New Roman';">Background: </span></strong><span lang="EN-US" style="mso-bidi-font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: 'Times New Roman';">The study aimed to explore the value of using non-invasive prenatal tests (NIPT) in the second trimester of pregnancy for chromosomal abnormality screening in vitro fertilization in elderly pregnant women and to analyze the reasons for inconsistent screening results in northwest China. </span></p> <p class="MsoNormal"><strong style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="mso-bidi-font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: 'Times New Roman';">Methods:</span></strong><span lang="EN-US" style="mso-bidi-font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: 'Times New Roman';"> A total of 47,286 pregnant women aged 19-51 who underwent prenatal examinations were collected. NIPT detection found that the positive rate of pregnant women aged >35 with spontaneous pregnancy was 0.78%, and the positive rate of in vitro fertilization pregnancy was 0.82%. Then, the detection accuracy of NIPT for pregnant women aged >35 with in vitro fertilization was further analyzed. </span></p> <p class="MsoNormal"><strong style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="mso-bidi-font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: 'Times New Roman';">Results:</span></strong><span lang="EN-US" style="mso-bidi-font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: 'Times New Roman';"> NIPT's sensitivity, specificity, and positive predictive value in detecting common chromosomal aneuploidies (T21, T18, and T13) in pregnant women aged >35 who received in vitro fertilization were 99.72%, 99.78%, and 66.45%, respectively. The mean gestational age, pregnancy number, AFP, and free β-HCG significantly differed between the positive and false positive groups (<em style="mso-bidi-font-style: normal;">P</em> < 0.05). Logistic analysis showed that the mean gestational age and AFP were independent risk factors for the failure of NIPT diagnosis (<em style="mso-bidi-font-style: normal;">P </em>< 0.05). <a name="OLE_LINK3"></a></span></p> <p class="MsoNormal"><span style="mso-bookmark: OLE_LINK3;"><strong style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="mso-bidi-font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: 'Times New Roman';">Conclusions: </span></strong></span><span style="mso-bookmark: OLE_LINK3;"><span lang="EN-US" style="mso-bidi-font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: 'Times New Roman';">NIPT has a particular detection performance for common chromosomal aneuploidies in vitro fertilization in pregnant women</span></span><span lang="EN-US" style="mso-bidi-font-size: 12.0pt; line-height: 150%; mso-bidi-font-family: 'Times New Roman';">. However, factors affecting detection accuracies must be considered when using it.</span></p>2025-05-13T00:00:00+02:00Copyright (c) 2025 Shuyuan Xue, Lixia Wang, Zhen Yu, Jingying Zhu, Le Feng, Guifeng Din, Penggao Daihttps://aseestant.ceon.rs/index.php/jomb/article/view/57804Development and Validation of a Nomogram Model to Predict Coronary Heart Disease in Snoring Patients With Hypertension and Non-glucose Metabolism Disorders2025-11-02T15:27:05+01:00Zhen WeiWeizhen10242024@163.comMenghui Wang1877491950@qq.comXiaoguang Yao3466153@qq.comLiang Mingwszsydxs@163.comXintian Caicaixt95@163.comNanfang Liweiz2025@163.com<p class="MsoNormal" style="line-height: 150%; mso-pagination: widow-orphan;"><strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: Tahoma;">Background: </span></strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: Tahoma;">We developed and validated a nomogram to predict the risk of coronary heart disease in hypertensive patients who snore, excluding those with glucose metabolism disorders. </span></p> <p class="MsoNormal" style="line-height: 150%; mso-pagination: widow-orphan;"><strong style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: Tahoma;">Methods: </span></strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: Tahoma;">Records from 2105 snoring patients with hypertension and non-glucose metabolism disorders. A random grouping technique was utilized to split the data into validation and derivation datasets (split ratio = 0.7: 0.3). Least absolute shrinkage and selection operator regression was applied to select predictors and constructed a nomogram model based on multivariate Cox regression analysis. The discrimination and consistency of the nomogram were evaluated using the area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analysis (DCA) to assess its performance. We found age, male, waist-to-height ratio (WHtR), low and high-density lipoprotein cholesterol (LDL-C and HDL-C), and apnea index (AI) identified as predictors to generate this nomogram model. </span></p> <p class="MsoNormal" style="line-height: 150%; mso-pagination: widow-orphan;"><strong style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: Tahoma;">Results: </span></strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: Tahoma;">The C-index at 84 months was 0.703 (95% confidence interval 0.653–0.754) in the derivation set and 0.645 (95% confidence interval 0.562–0.728) in the validation set. The nomogram demonstrated good performance in the calibration curve and DCA. </span></p> <p class="MsoNormal" style="line-height: 150%; mso-pagination: widow-orphan;"><strong style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: Tahoma;">Conclusions: </span></strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: Tahoma;">So, our study proposed an effective nomogram model with potential application value for individualized prediction of coronary heart disease outcomes in snoring individuals with hypertension, excluding glucose metabolism disorders. And “AI” was proposed as a novel predictor.</span></p>2025-05-13T00:00:00+02:00Copyright (c) 2025 Zhen Wei, Menghui Wang, Xiaoguang Yao, Liang Ming, Xintian Cai, Nanfang Lihttps://aseestant.ceon.rs/index.php/jomb/article/view/56797The Impact of PDCA Cycle-Driven Nutritional Support on serum Biomarkers and Quality of Life and in Nasopharyngeal Carcinoma Patients Undergoing Radiotherapy2025-11-02T16:25:41+01:00Weiming Xiong35462541642@163.comJinying Mo541748161422@163.comJingjin Weng674675685862@163.comYongli Wang7151781654232@163.comJiazhang Wei156632313671@163.comLinsong Ye97834609653@163.comMin Li82451857253@163.comShenhong Quqshdoctor1@126.com<p class="MsoNormal"><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">Aim:This study aimed to evaluate the effectiveness of nutritional support guided by the PDCA cycle management model in nasopharyngeal carcinoma (NPC) patients undergoing radiotherapy. </span></p> <p class="MsoNormal"><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">Methods:A total of 100 NPC patients were randomly assigned to an observation group (OG) (n = 50) and a control group (CG) (n = 50). The CG received routine nutritional support, while the OG received PDCA cycle-based nutritional support. Key outcomes included blood nutritional biomarkers, quality of life (QoL), incidence of adverse reactions (ARs), and clinical efficacy.</span></p> <p class="MsoNormal"><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">Results: Post-treatment analysis revealed that the OG had a significantly higher total effective rate (72%) compared to the CG (38%) (P < 0.05). The OG demonstrated higher albumin, prealbumin, and total protein levels, along with lower CRP levels after treatment. Additionally, significant improvements were observed in cognitive, role, social, physical, and emotional functioning in the OG (P < 0.05). Furthermore, the AR rate was significantly lower in the OG (20%) compared to the CG (36%) (P < 0.05).</span></p> <p class="MsoNormal"><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">Conclusion: These findings suggest that PDCA cycle-based nutritional support improves clinical efficacy and QoL, minimizes nutritional risks and ARs, and enhances overall safety in NPC patients undergoing radiotherapy. Serum markers such as serum iron, ferritin, prealbumin, and CRP were effective in monitoring the impact of nutritional interventions<span style="mso-bidi-font-weight: bold;"> on patients’ nutritional and inflammatory status.</span></span></p>2025-05-13T00:00:00+02:00Copyright (c) 2025 Shenhong Quhttps://aseestant.ceon.rs/index.php/jomb/article/view/58247Changes in nutrient proteins, inflammatory factors and immunoglobulins before and after enteral nutritional support in patients with cerebral hemorrhage2025-11-02T16:26:39+01:00Xiaolu Tang15829388249@163.comWenjun Tan18709240140@163.comXiaoqiang Li424206889@qq.com<p>Objective: Enteral nutrition support (ENS) is one of the necessary measures after surgical treatment of modern cerebral hemorrhage (CH), and this study will analyze the changes in nutrient proteins, inflammatory factors, and immunoglobulins before and after ENS in patients with CH, which will serve as a reference for future clinics when performing ENS.</p> <p>Methods: 160 ICH patients (76 in the intermittent group and 84 in the continuous group) were included, and changes in indicators before and after EN intervention were retrospectively analyzed in both groups. Including nutrient proteins (albumin ALB, transferrin TRF, prealbumin PAB), inflammatory factors (IL-1β, IL-6, TNF-α), immunoglobulins (IgA, IgG, IgM) and gastrointestinal tolerance.</p> <p>Results: There was no difference in adverse reactions between the two groups during ENS (P>0.05).After ENS, ALB, TRF, PAB, IgA, IgG, and IgM were significantly increased in both groups, while IL-1β, IL-6, and TNF-α were decreased (P<0.05). After ENS, there was no difference in nutrient proteins between the two groups (P>0.05), but inflammatory factors were lower in the intermittent group than in the continuous group, while immunoglobulins were higher than in the intermittent group (P<0.05).</p> <p>Conclusion: ENS constitutes the core mechanism of neuroprotection through a multilayered linkage of “metabolic substrate supply - intestinal barrier repair - immune phenotype remodeling - inflammatory signaling inhibition”.</p>2025-05-16T00:00:00+02:00Copyright (c) 2025 Xiaolu Tang, Wenjun Tan, Xiaoqiang Lihttps://aseestant.ceon.rs/index.php/jomb/article/view/57224Clinical and diagnosis value of serum Cortisol, TNF-α, albumin in ovarian cancer patients2025-11-02T16:27:36+01:00Rong Jiang819320884@qq.comXin Panapansw@126.comXiu Shi375493989@qq.comJinhua Zhoujsjhzh@126.comJuan Wangwangjuan@suda.edu.cnHong Zhang18013100835@163.comJingjing Majjma@suda.edu.cn<p class="MsoNormal"><strong><em><span style="mso-bidi-font-size: 10.5pt; font-family: 'Times New Roman',serif;">Objective: </span></em></strong><span style="mso-bidi-font-size: 10.5pt; font-family: 'Times New Roman',serif;">This research aimed to evaluate the prognostic value of serum serum Cortisol, TNF-α, albumin in selecting treatment methods for advanced ovarian cancer (OC) patients<strong><em>.</em></strong></span></p> <p class="MsoNormal"><strong><em><span style="mso-bidi-font-size: 10.5pt; font-family: 'Times New Roman',serif;">Methods: </span></em></strong><span style="mso-bidi-font-size: 10.5pt; font-family: 'Times New Roman',serif;">A retrospective analysis was conducted on OC patients undergoing surgery at our hospital from June 2022 to June 2024 with complete clinical and pathological data. Patients were categorized into low ALB (< 35 g/L) and normal ALB (</span><span lang="ZH-CN" style="mso-bidi-font-size: 10.5pt; font-family: SimSun; mso-ascii-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-hansi-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman';">≥</span><span style="mso-bidi-font-size: 10.5pt; font-family: 'Times New Roman',serif;"> 35 g/L) groups based on pretreatment serum ALB levels. Each group was further divided into primary debulking surgery (PDS) and neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) subgroups. Clinicopathologic characteristics were analyzed.</span></p> <p class="MsoNormal"><strong><em><span style="mso-bidi-font-size: 10.5pt; font-family: 'Times New Roman',serif;">Results</span></em></strong><span style="mso-bidi-font-size: 10.5pt; font-family: 'Times New Roman',serif;">: Pretreatment serum ALB levels positively correlated with progression-free survival (PFS) (r = 0.2989, P < 0.05) and overall survival (OS) (r = 0.2702, P < 0.05), with the low ALB group exhibiting significantly lower PFS and OS (P < 0.05). In the low ALB group, significant differences were observed between PDS and NACT-IDS in ascitic fluid level, R0 cytoreduction rate, postoperative complications, and length of stay (P < 0.05), though PFS and OS were comparable (P > 0.05). Similarly, in the normal ALB group, significant differences were noted in FIGO staging, ascitic fluid level, hemoglobin (HGB) levels, intraoperative hemorrhage, blood transfusion volume, R0 cytoreduction rate, and length of stay (P < 0.05), while PFS and OS remained unaffected by treatment type (P > 0.05). Additionally, C-reactive protein (CRP) levels were significantly higher in the low ALB group (6.5 ± 1.1 mg/L vs. 5.2 ± 1.0 mg/L, P < 0.05), indicating greater inflammation, whereas HGB levels were significantly lower (110.4 ± 15.8 g/L vs. 118.7 ± 10.5 g/L, P = 0.021), reflecting poorer nutritional status. Tumor necrosis factor-alpha (TNF-α) levels showed a non-significant upward trend (P = 0.058), while cortisol levels were similar between groups (P = 0.073).</span></p> <p class="MsoNormal"><strong><em><span style="mso-bidi-font-size: 10.5pt; font-family: 'Times New Roman',serif;">Conclusion</span></em></strong><span style="mso-bidi-font-size: 10.5pt; font-family: 'Times New Roman',serif;">: Selecting NACT-IDS for advanced OC patients with hypoalbuminemia can reduce incidence of postoperative complications and elevate cytoreductive effect. Thus, hypoalbuminemia can serve as a reference indicator for advanced OC patients to choose NACT-IDS.</span></p>2025-05-21T00:00:00+02:00Copyright (c) 2025 Rong Jiang, Xin Pan, Xiu Shi, Jinhua Zhou, Juan Wang, Hong Zhang, Jingjing Mahttps://aseestant.ceon.rs/index.php/jomb/article/view/58244ACCEPTANCE AND COMMITMENT THERAPY MODULATES IMMUNEINFLAMMATORY RESPONSES AND NEUROTROPHIC FACTORS HOMEOSTASIS IN ELDERLY STROKE PATIENTS: A RANDOMIZED CONTROLLED TRIAL2025-11-02T16:28:30+01:00Jing Wangjamine2@126.comHaiyan Gunbguhaiyan_2008@163.comXiaorong Hurong070866@126.comYanjie Zhounanchangyanjie@163.comLingling Wu18268659647@163.com<p>Objective: This study examined the regulatory effects of Acceptance and Commitment Therapy (ACT) on T lymphocyte subsets, serum inflammatory cytokines, neurotransmitters, and oxidative stress markers in elderly cerebral stroke (CS) patients, providing insights into the multi-dimensional pathophysiological interactions and potential intervention strategies for chronic stroke recovery.</p> <p>Methods: In this randomized controlled trial, 120 elderly stroke patients were allocated to either an ACT group (ACT intervention; n=60) or a routine group (conventional treatment; n=60). Comprehensive assessments were performed to quantify: (1) peripheral T lymphocyte distribution (CD3+, CD4+, CD8+ subsets, and CD4+/CD8+ ratio), (2) serum inflammatory cytokines (IL-1β, IL-6, IL-10, and TNF-α), (3) neurotransmitters (5-HT, NE, BDNF, and IGF-1), and (4) oxidative stress markers (SOD, MDA, CAT, and NO) using flow cytometry, HPLC-ECD, and ELISA. Statistical analyses were conducted with SPSS 22.0.</p> <p>Results: Following treatment, CS patients exhibited reduced CD3+ and CD4+ T-cell levels along with a decreased CD4+/CD8+ ratio, while CD8+ T-cell proportions were elevated (P<0.05). Proinflammatory cytokine levels (IL-1β, IL-6, and TNF-α) were significantly suppressed, whereas anti-inflammatory IL-10 expression increased (P<0.05). Notably, ACT demonstrated superior efficacy in restoring immune balance and attenuating inflammation compared to conventional intervention (P<0.05). Furthermore, neurotransmitter levels were elevated, and oxidative stress markers were ameliorated in CS after treatment (P<0.05), suggesting that ACT enhances neurotrophic activity and mitigates oxidative injury.</p> <p>Conclusion: ACT likely confers neuroprotection through multi-target mechanisms, including modulation of T-cell subset homeostasis, upregulation of neurotrophic factors, and suppression of oxidative stress. These findings provide a scientific foundation for integrating ACT into a psychobiological rehabilitation framework for elderly CS patients.</p>2025-05-21T00:00:00+02:00Copyright (c) 2025 Lingling Wu, Jing Wang, Haiyan Gu, Xiaorong Hu, Yanjie Zhouhttps://aseestant.ceon.rs/index.php/jomb/article/view/54841Association of miR-223-3p and miR-223-5p gene expression with Levels of IgE, Vitamin D and Mg+2 in pediatric Asthma patients 2025-11-02T16:29:41+01:00Duaa F. Al-Mashhadanidoaaff597@gmail.comBasima Q. Alsaadibasima@ige.uobaghdad.edu.iq<p class="MsoNormal" style="margin-bottom: .0001pt; text-align: justify; line-height: 150%;"><strong><span style="font-size: 12.0pt; line-height: 150%; font-family: HelveticaNeueLTStd-Lt; mso-bidi-font-family: HelveticaNeueLTStd-Lt;">Background:</span></strong><span style="font-size: 12.0pt; line-height: 150%; font-family: HelveticaNeueLTStd-Lt; mso-bidi-font-family: HelveticaNeueLTStd-Lt;"> Asthma, a global non-communicable disease, significantly impacts public health. Severe cases cause high morbidity and mortality rates, with childhood asthma rates in Iraq reaching 20%. </span><span style="font-size: 13.0pt; line-height: 150%; font-family: HelveticaNeueLTStd-Lt; mso-bidi-font-family: HelveticaNeueLTStd-Lt;">The study investigated the expression levels of miR-223-3p and miR-223-5p genes linked to pediatric asthma and the impact of IgE, Vitamin D, and Mg+2 on asthma severity.</span></p> <p class="MsoNormal" style="margin-bottom: .0001pt; text-align: justify; line-height: 150%;"><strong><span style="font-size: 13.0pt; line-height: 150%; font-family: HelveticaNeueLTStd-Lt; mso-bidi-font-family: HelveticaNeueLTStd-Lt;">Methods:</span></strong> <span style="font-size: 12.0pt; line-height: 150%; font-family: HelveticaNeueLTStd-Lt; mso-bidi-font-family: HelveticaNeueLTStd-Lt;">A study of 140 children aged 1-10 years with allergic asthma was conducted in Baghdad from November 2023 to February 2024. The patients were divided into three groups: those under 1, those aged 1-5, and those over 5. Serum IgE, Vit D3, and Mg+2 levels were determined using the Immunoglobulin E Test Kit.</span></p> <p> </p> <p class="MsoNormal" style="margin-bottom: .0001pt; text-align: justify; line-height: 150%;"><strong><span style="font-size: 13.0pt; line-height: 150%; font-family: HelveticaNeueLTStd-Lt; mso-bidi-font-family: HelveticaNeueLTStd-Lt;">Results:</span></strong><span style="font-size: 12.0pt; line-height: 150%; font-family: HelveticaNeueLTStd-Lt; mso-bidi-font-family: HelveticaNeueLTStd-Lt;"> The results indicated a significant increase in the level of IgE in patients (353.812 ± 25.679 ng/ml) compared to the control group (25.320 ± 2.581 ng/ml) (p-value < 0.01, the serum level of Vit-D revealed a significant decrease in the patient group (16.907 ± 0.512 ng/mL) while in the control group, levels reached (32.746 ± 1.629 ng/mL), Mg⁺² serum level decreased in patient groups (2.168 ± 0.030 ng/dL) compared to control group (2.316 ± 0.028 ng/dL) at p-value < 0.01. also, this study shows that upregulation of gene expression in miR-223-3p and miR-223-5p genes are considered risk factors for allergic asthma. </span><strong><span style="font-size: 13.0pt; line-height: 150%; font-family: HelveticaNeueLTStd-Lt; mso-bidi-font-family: HelveticaNeueLTStd-Lt;">Conclusion:</span></strong><span style="font-size: 12.0pt; line-height: 150%; font-family: HelveticaNeueLTStd-Lt; mso-bidi-font-family: HelveticaNeueLTStd-Lt;"> The study found that asthma patients had high IgE levels, low vitamin D3 and magnesium levels, and high gene expression in miR-223-3p and miR-223-5p genes, risk factors for allergic asthma.</span></p>2025-08-20T00:00:00+02:00Copyright (c) 2025 Duaa F. Al-Mashhadani, Basima Q. Alsaadihttps://aseestant.ceon.rs/index.php/jomb/article/view/57933Role of Growth Hormone/Insulin-Like Growth Factor-1 Axis Dysfunction and Inflammatory Cytokines in Pediatric Short Stature2025-11-18T10:12:34+01:00Qingfu Yangwutieniu1618@aliyun.comShanshan Chen134864428721@163.comTieniu Wu18879729120@163.comJingxin Peng18879729120@163.comLidan Mao13486442872@163.com<p class="MsoNormal" style="text-align: justify; text-justify: kashida; text-kashida: 0%;"><strong><span style="font-size: 12.0pt; line-height: 107%; font-family: 'Times New Roman',serif; mso-ascii-theme-font: major-bidi; mso-hansi-theme-font: major-bidi; mso-bidi-theme-font: major-bidi;">Background:</span></strong><span style="font-size: 12.0pt; line-height: 107%; font-family: 'Times New Roman',serif; mso-ascii-theme-font: major-bidi; mso-hansi-theme-font: major-bidi; mso-bidi-theme-font: major-bidi;"> Pediatric short stature is a prevalent clinical issue, often linked to dysfunction in the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis. Recent research suggests that inflammatory cytokines and serum markers may play a role in this dysfunction. This study aims to explore the molecular mechanisms contributing to GH/IGF-1 axis dysfunction, along with the levels of inflammatory cytokines and other relevant markers in children with short stature.</span></p> <p class="MsoNormal" style="text-align: justify; text-justify: kashida; text-kashida: 0%;"><strong><span style="font-size: 12.0pt; line-height: 107%; font-family: 'Times New Roman',serif; mso-ascii-theme-font: major-bidi; mso-hansi-theme-font: major-bidi; mso-bidi-theme-font: major-bidi;">Methods:</span></strong><span style="font-size: 12.0pt; line-height: 107%; font-family: 'Times New Roman',serif; mso-ascii-theme-font: major-bidi; mso-hansi-theme-font: major-bidi; mso-bidi-theme-font: major-bidi;"> 150 children diagnosed with short stature (defined as height below the 3rd percentile for age and sex) were recruited from the endocrinology ward of a tertiary care hospital. A control group of 150 age- and sex-matched healthy children was included for comparison. Serum levels of GH, IGF-1, interleukin-6 (IL-6), interleukin-8 (IL-8), and other relevant markers were measured using enzyme-linked immunosorbent assay (ELISA). Genetic analysis was performed to identify potential mutations in GH/IGF-1 axis-related genes. Data were analyzed using SPSS software, with statistical significance set at p < 0.05.</span></p> <p class="MsoNormal" style="text-align: justify; text-justify: kashida; text-kashida: 0%;"><strong><span style="font-size: 12.0pt; line-height: 107%; font-family: 'Times New Roman',serif; mso-ascii-theme-font: major-bidi; mso-hansi-theme-font: major-bidi; mso-bidi-theme-font: major-bidi;">Results:</span></strong><span style="font-size: 12.0pt; line-height: 107%; font-family: 'Times New Roman',serif; mso-ascii-theme-font: major-bidi; mso-hansi-theme-font: major-bidi; mso-bidi-theme-font: major-bidi;"> Children with short stature exhibited significantly lower serum levels of GH and IGF-1 compared to controls (p < 0.001). Elevated levels of IL-6 and IL-8 were found in the short stature group (p < 0.01). Genetic analysis revealed a higher frequency of mutations in the growth hormone receptor (GHR) gene in the short stature cohort. Correlation analysis showed a negative association between serum IL-6 levels and IGF-1 levels (r = -0.45, p < 0.001).</span></p> <p class="MsoNormal" style="text-align: justify; text-justify: kashida; text-kashida: 0%;"><strong><span style="font-size: 12.0pt; line-height: 107%; font-family: 'Times New Roman',serif; mso-ascii-theme-font: major-bidi; mso-hansi-theme-font: major-bidi; mso-bidi-theme-font: major-bidi;">Conclusion:</span></strong><span style="font-size: 12.0pt; line-height: 107%; font-family: 'Times New Roman',serif; mso-ascii-theme-font: major-bidi; mso-hansi-theme-font: major-bidi; mso-bidi-theme-font: major-bidi;"> This study provides evidence that dysfunction in the GH/IGF-1 axis, along with elevated inflammatory cytokines, may contribute to the pathogenesis of pediatric short stature. Further research is needed to investigate potential therapeutic targets and interventions aimed at addressing these molecular mechanisms.</span></p>2025-07-02T00:00:00+02:00Copyright (c) 2025 Lidan Maohttps://aseestant.ceon.rs/index.php/jomb/article/view/58169Molecular regulatory mechanisms of depression-related thrombosis risk2025-11-02T16:31:52+01:00dr pdrwei6xx@163.com<p><!-- [if !mso]> <style> v\:* {behavior:url(#default#VML);} o\:* {behavior:url(#default#VML);} w\:* {behavior:url(#default#VML);} .shape {behavior:url(#default#VML);} </style> <![endif]--><!-- [if gte mso 9]><xml> <o:OfficeDocumentSettings> <o:AllowPNG/> </o:OfficeDocumentSettings> </xml><![endif]--><!-- [if gte mso 9]><xml> <w:WordDocument> <w:View>Normal</w:View> <w:Zoom>0</w:Zoom> <w:TrackMoves/> <w:TrackFormatting/> <w:PunctuationKerning/> <w:ValidateAgainstSchemas/> <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid> <w:IgnoreMixedContent>false</w:IgnoreMixedContent> <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText> <w:DoNotPromoteQF/> <w:LidThemeOther>EN-US</w:LidThemeOther> <w:LidThemeAsian>X-NONE</w:LidThemeAsian> <w:LidThemeComplexScript>AR-SA</w:LidThemeComplexScript> <w:Compatibility> <w:BreakWrappedTables/> <w:SnapToGridInCell/> <w:WrapTextWithPunct/> <w:UseAsianBreakRules/> <w:DontGrowAutofit/> <w:SplitPgBreakAndParaMark/> <w:EnableOpenTypeKerning/> <w:DontFlipMirrorIndents/> <w:OverrideTableStyleHps/> </w:Compatibility> <w:DoNotOptimizeForBrowser/> <m:mathPr> <m:mathFont m:val="Cambria Math"/> <m:brkBin m:val="before"/> <m:brkBinSub m:val="--"/> <m:smallFrac m:val="off"/> <m:dispDef/> <m:lMargin m:val="0"/> <m:rMargin m:val="0"/> <m:defJc m:val="centerGroup"/> <m:wrapIndent m:val="1440"/> <m:intLim m:val="subSup"/> <m:naryLim m:val="undOvr"/> </m:mathPr></w:WordDocument> </xml><![endif]--><!-- [if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="false" DefSemiHidden="false" DefQFormat="false" DefPriority="99" LatentStyleCount="371"> <w:LsdException Locked="false" Priority="0" QFormat="true" Name="Normal"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 1"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 2"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 3"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 4"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 5"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 6"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 7"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 8"/> <w:LsdException Locked="false" Priority="9" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="heading 9"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 5"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 6"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 7"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 8"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index 9"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 1"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 2"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 3"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 4"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 5"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 6"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 7"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 8"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" Name="toc 9"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Normal Indent"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="footnote text"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="annotation text"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="header"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="footer"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="index heading"/> <w:LsdException Locked="false" Priority="35" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="caption"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="table of figures"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="envelope address"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="envelope return"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="footnote reference"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="annotation reference"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="line number"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="page number"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="endnote reference"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="endnote text"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="table of authorities"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="macro"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="toa heading"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Bullet"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Number"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List 5"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Bullet 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Bullet 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Bullet 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Bullet 5"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Number 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Number 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Number 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Number 5"/> <w:LsdException Locked="false" Priority="0" QFormat="true" Name="Title"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Closing"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Signature"/> <w:LsdException Locked="false" Priority="1" SemiHidden="true" UnhideWhenUsed="true" Name="Default Paragraph Font"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text Indent"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Continue"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Continue 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Continue 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Continue 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="List Continue 5"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Message Header"/> <w:LsdException Locked="false" Priority="11" QFormat="true" Name="Subtitle"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Salutation"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Date"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text First Indent"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text First Indent 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Note Heading"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text Indent 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Body Text Indent 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Block Text"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Hyperlink"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="FollowedHyperlink"/> <w:LsdException Locked="false" Priority="22" QFormat="true" Name="Strong"/> <w:LsdException Locked="false" Priority="20" QFormat="true" Name="Emphasis"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Document Map"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Plain Text"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="E-mail Signature"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Top of Form"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Bottom of Form"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Normal (Web)"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Acronym"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Address"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Cite"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Code"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Definition"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Keyboard"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Preformatted"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Sample"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Typewriter"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="HTML Variable"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Normal Table"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="annotation subject"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="No List"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Outline List 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Outline List 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Outline List 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Simple 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Simple 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Simple 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Classic 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Classic 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Classic 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Classic 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Colorful 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Colorful 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Colorful 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Columns 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Columns 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Columns 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Columns 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Columns 5"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 5"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 6"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 7"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Grid 8"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 4"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 5"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 6"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 7"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table List 8"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table 3D effects 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table 3D effects 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table 3D effects 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Contemporary"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Elegant"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Professional"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Subtle 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Subtle 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Web 1"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Web 2"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Web 3"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Balloon Text"/> <w:LsdException Locked="false" Priority="39" Name="Table Grid"/> <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true" Name="Table Theme"/> <w:LsdException Locked="false" SemiHidden="true" Name="Placeholder Text"/> <w:LsdException Locked="false" Priority="1" QFormat="true" Name="No Spacing"/> <w:LsdException Locked="false" Priority="60" Name="Light Shading"/> <w:LsdException Locked="false" Priority="61" Name="Light List"/> <w:LsdException Locked="false" Priority="62" Name="Light Grid"/> <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1"/> <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2"/> <w:LsdException Locked="false" Priority="65" Name="Medium List 1"/> <w:LsdException Locked="false" Priority="66" Name="Medium List 2"/> <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1"/> <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2"/> <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3"/> <w:LsdException Locked="false" Priority="70" Name="Dark List"/> <w:LsdException Locked="false" Priority="71" Name="Colorful Shading"/> <w:LsdException Locked="false" Priority="72" Name="Colorful List"/> <w:LsdException Locked="false" Priority="73" Name="Colorful Grid"/> <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 1"/> <w:LsdException Locked="false" Priority="61" Name="Light List Accent 1"/> <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 1"/> <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 1"/> <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 1"/> <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 1"/> <w:LsdException Locked="false" SemiHidden="true" Name="Revision"/> <w:LsdException Locked="false" Priority="34" QFormat="true" Name="List Paragraph"/> <w:LsdException Locked="false" Priority="29" QFormat="true" Name="Quote"/> <w:LsdException Locked="false" Priority="30" QFormat="true" Name="Intense Quote"/> <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 1"/> <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 1"/> <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 1"/> <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 1"/> <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 1"/> <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 1"/> <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 1"/> <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 1"/> <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 2"/> <w:LsdException Locked="false" Priority="61" Name="Light List Accent 2"/> <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 2"/> <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 2"/> <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 2"/> <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 2"/> <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 2"/> <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 2"/> <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 2"/> <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 2"/> <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 2"/> <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 2"/> <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 2"/> <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 2"/> <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 3"/> <w:LsdException Locked="false" Priority="61" Name="Light List Accent 3"/> <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 3"/> <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 3"/> <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 3"/> <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 3"/> <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 3"/> <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 3"/> <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 3"/> <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 3"/> <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 3"/> <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 3"/> <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 3"/> <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 3"/> <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 4"/> <w:LsdException Locked="false" Priority="61" Name="Light List Accent 4"/> <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 4"/> <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 4"/> <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 4"/> <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 4"/> <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 4"/> <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 4"/> <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 4"/> <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 4"/> <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 4"/> <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 4"/> <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 4"/> <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 4"/> <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 5"/> <w:LsdException Locked="false" Priority="61" Name="Light List Accent 5"/> <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 5"/> <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 5"/> <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 5"/> <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 5"/> <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 5"/> <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 5"/> <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 5"/> <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 5"/> <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 5"/> <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 5"/> <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 5"/> <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 5"/> <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 6"/> <w:LsdException Locked="false" Priority="61" Name="Light List Accent 6"/> <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 6"/> <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 6"/> <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 6"/> <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 6"/> <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 6"/> <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 6"/> <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 6"/> <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 6"/> <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 6"/> <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 6"/> <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 6"/> <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 6"/> <w:LsdException Locked="false" Priority="19" QFormat="true" Name="Subtle Emphasis"/> <w:LsdException Locked="false" Priority="21" QFormat="true" Name="Intense Emphasis"/> <w:LsdException Locked="false" Priority="31" QFormat="true" Name="Subtle Reference"/> <w:LsdException Locked="false" Priority="32" QFormat="true" Name="Intense Reference"/> <w:LsdException Locked="false" Priority="33" QFormat="true" Name="Book Title"/> <w:LsdException Locked="false" Priority="37" SemiHidden="true" UnhideWhenUsed="true" Name="Bibliography"/> <w:LsdException Locked="false" Priority="39" SemiHidden="true" UnhideWhenUsed="true" QFormat="true" Name="TOC Heading"/> <w:LsdException Locked="false" Priority="41" Name="Plain Table 1"/> <w:LsdException Locked="false" Priority="42" Name="Plain Table 2"/> <w:LsdException Locked="false" Priority="43" Name="Plain Table 3"/> <w:LsdException Locked="false" Priority="44" Name="Plain Table 4"/> <w:LsdException Locked="false" Priority="45" Name="Plain Table 5"/> <w:LsdException Locked="false" Priority="40" Name="Grid Table Light"/> <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light"/> <w:LsdException Locked="false" Priority="47" Name="Grid Table 2"/> <w:LsdException Locked="false" Priority="48" Name="Grid Table 3"/> <w:LsdException Locked="false" Priority="49" Name="Grid Table 4"/> <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark"/> <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful"/> <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful"/> <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light Accent 1"/> <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 1"/> <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 1"/> <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 1"/> <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 1"/> <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful Accent 1"/> <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful Accent 1"/> <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light Accent 2"/> <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 2"/> <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 2"/> <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 2"/> <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 2"/> <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful Accent 2"/> <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful Accent 2"/> <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light Accent 3"/> <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 3"/> <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 3"/> <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 3"/> <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 3"/> <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful Accent 3"/> <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful Accent 3"/> <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light Accent 4"/> <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 4"/> <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 4"/> <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 4"/> <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 4"/> <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful Accent 4"/> <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful Accent 4"/> <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light Accent 5"/> <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 5"/> <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 5"/> <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 5"/> <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 5"/> <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful Accent 5"/> <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful Accent 5"/> <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light Accent 6"/> <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 6"/> <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 6"/> <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 6"/> <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 6"/> <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful Accent 6"/> <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful Accent 6"/> <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light"/> <w:LsdException Locked="false" Priority="47" Name="List Table 2"/> <w:LsdException Locked="false" Priority="48" Name="List Table 3"/> <w:LsdException Locked="false" Priority="49" Name="List Table 4"/> <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark"/> <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful"/> <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful"/> <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light Accent 1"/> <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 1"/> <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 1"/> <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 1"/> <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 1"/> <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful Accent 1"/> <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful Accent 1"/> <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light Accent 2"/> <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 2"/> <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 2"/> <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 2"/> <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 2"/> <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful Accent 2"/> <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful Accent 2"/> <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light Accent 3"/> <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 3"/> <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 3"/> <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 3"/> <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 3"/> <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful Accent 3"/> <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful Accent 3"/> <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light Accent 4"/> <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 4"/> <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 4"/> <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 4"/> <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 4"/> <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful Accent 4"/> <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful Accent 4"/> <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light Accent 5"/> <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 5"/> <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 5"/> <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 5"/> <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 5"/> <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful Accent 5"/> <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful Accent 5"/> <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light Accent 6"/> <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 6"/> <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 6"/> <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 6"/> <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 6"/> <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful Accent 6"/> <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful Accent 6"/> </w:LatentStyles> </xml><![endif]--><!-- [if gte mso 10]> <style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Cambria","serif";} </style> <![endif]--></p> <p class="Abstract" style="margin: 0cm; margin-bottom: .0001pt; text-align: justify; line-height: 200%;"><strong><span style="font-family: 'Times New Roman','serif';">Background: </span></strong><span style="font-family: 'Times New Roman','serif';">This is largely because depression is a common psychiatric condition affecting more than 280 million people worldwide and is increasingly linked to an increased risk of thrombotic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE). For example, underlying pathophysiological mechanisms remain inadequatly understood and thus further research on the association between depression, systemic inflammation, platelet activation and coagulation abnormalities is warranted. The objective of this study is to identify biological pathways linking thombosis and depression by examination of inflammatory and coagulation biomarkers, platelet activation, and risk of thrombosis independent predictors. In addition, the study investigates the possibility of nursing interventions in reducing thrombotic complications among depressed individuals. </span></p> <p class="Abstract" style="margin: 0cm; margin-bottom: .0001pt; text-align: justify; line-height: 200%;"><strong><span style="font-family: 'Times New Roman','serif';">Methods:</span></strong><span style="font-family: 'Times New Roman','serif';"> A case control study was performed with 500 subjects (250 who had major depressive disorder and 250 healthy control subjects) were included. Enzyme-linked immunosorbent assays (ELISA) and quantitative polymerase chain reaction (qPCR) were employed to quantify key inflammatory (IL-6, TNF-</span><span style="font-size: 11.0pt; line-height: 107%; font-family: 'Calibri','sans-serif'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi; position: relative; top: 2.5pt; mso-text-raise: -2.5pt; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><img src="file:///C:\Users\205055~1\AppData\Local\Temp\msohtmlclip1\01\clip_image002.png" width="8" height="36" /></span><span style="font-family: 'Times New Roman','serif';">, CRP) and coagulation (D-dimer, fibrinogen) biomarkers. An assessment of platelet activation (CD62P, PAC1 binding, GPIIbIIIa activation) was performed by flow cytometry. The study was carried out by a longitudinal follow-up over 12 months and by multivariate regression models to identify independent risk predictors. </span></p> <p class="Abstract" style="margin: 0cm; margin-bottom: .0001pt; text-align: justify; line-height: 200%;"><strong><span style="font-family: 'Times New Roman','serif';">Results:</span></strong><span style="font-family: 'Times New Roman','serif';"> Thrombophilic and inflammatory parameters were significantly higher in depressed patients as compared to controls (p<span style="mso-spacerun: yes;"> </span>0.001). The system was markedly hypercoagulable, as platelet activation markers were greatly upregulated. Through multivariate regression analysis, we determined that thrombosis risk was independent of severity level of depression (OR = 2.10, p<span style="mso-spacerun: yes;"> </span>0.001), IL-6 levels (OR = 1.92, p<span style="mso-spacerun: yes;"> </span>0.001), and platelet activation (OR = 2.50, p<span style="mso-spacerun: yes;"> </span>0.001). </span></p> <p class="Abstract" style="margin: 0cm; margin-bottom: .0001pt; text-align: justify; line-height: 200%;"><strong><span style="font-family: 'Times New Roman','serif';">Conclusion:</span></strong><span style="font-family: 'Times New Roman','serif';"> The results indicate that depression is an independent risk factor for thrombosis, through systemic inflammation and platelet hyperactivity. These results reinforce the value of licking psychiatric screening into thrombosis risk assessment and suggest the possible benefits of targeted anti-inflammatory or antiplatelet interventions in the psychiatric population at high risk of thrombosis.</span></p>2025-05-21T00:00:00+02:00Copyright (c) 2025 Weiwei Penghttps://aseestant.ceon.rs/index.php/jomb/article/view/54944Diagnostic value and Clinical Significance of serum Proteins Ki-67, PI3K, and Fascin in Patients with Oral Squamous Cell Carcinoma2025-11-02T16:32:44+01:00Jianming WeiJw58253275325@163.com<p class="MsoNormal"><strong style="mso-bidi-font-weight: normal;"><span style="font-family: 'Times New Roman',serif;">Objective: </span></strong><span style="font-family: 'Times New Roman',serif;">This study was designed to explore the expression and significance of KI-67, phosphoinositide-3-kinase (PI3K), and Fascin in oral squamous cell carcinoma (OSCC).</span> <strong style="mso-bidi-font-weight: normal;"><span style="font-family: 'Times New Roman',serif;">Methods:</span></strong><span style="font-family: 'Times New Roman',serif;"> Thirty-five patients with OSCC admitted to our hospital from January 2019 to December 2020 were included. Tumor tissue and paracancerous tissue samples of all patients were collected. Immunohistochemical staining was performed to determine the expression of Ki-67, PI3K, and Fascin. Pearson correlation analysis was employed to analyze the association of clinicopathological characteristics with Ki-67, PI3K, fascia, and oral cancer. SPSS 23.0 was used for data analysis. <strong style="mso-bidi-font-weight: normal;">Results:</strong> Significantly higher positive expression rates of Ki-67, PI3K, and Fascin were detected in OSCC tissues, well-differentiated OSCC tissues, and OSCC tissues with lymph node metastasis and cancer cells infiltrating to peripheral muscle, <em>vs</em> paracancerous tissues, moderately and poorly differentiated OSCC tissues, and OSCC tissues without lymph node metastasis, respectively (all P<0.05).</span> <span style="font-family: 'Times New Roman',serif;">The positive expression rates of Ki-67, PI3K, and Fascin were not statistically different between stage I+II and III+IV OSCC (P>0.05). Ki-67 was positively correlated with PI3K (r=0.930, P=0.019) and Fascin (r=0.928, P=0.019), and Fascin was positively correlated with PI3K (r=0.991, P=0.001). <strong style="mso-bidi-font-weight: normal;">Conclusion:</strong> The relative expression levels of Ki-67, PI3K, and Fascin are related to lymph node metastasis, perifocal muscle invasion, and pathological staging of patients with OSCC, which indicates their potential involvement in the occurrence and progression of <a name="OLE_LINK1"></a>OSCC.</span></p>2025-05-24T00:00:00+02:00Copyright (c) 2025 Jianming Weihttps://aseestant.ceon.rs/index.php/jomb/article/view/56889MARKERS OF INFLAMMATION AND IMMUNOLOGICAL COMPETENCE: ASSESSMENT IN THE EARLY POSTOPERATIVE PHASE OF CARDIAC SURGERY INVOLVING EXTRACORPOREAL CIRCULATION2025-11-02T16:33:36+01:00Selma Mutevelićsemutevelic@gmail.comLejla Bajramović-Omeragićbajramovic_lejla@hotmail.comMerima Šehićmerima.sehic@fzf.unsa.baSumejja Baljević-Spahićsumejjab@gmail.comBelma Pehlivanović Kellebelma.pehlivanovic@ffsa.unsa.baErmin Begovićbegovic.ermin@hotmail.comBerina Hasanefendićbery-kurs@hotmail.comErmina Mujičićdr.emujicic@gmail.comMarina Delić-Šaracmarinadelicsarac@gmail.comDrago Batinićdrago.batinic@gmail.com<p class="MsoNormal" style="margin-bottom: 0in; text-align: justify; line-height: normal;"><strong style="mso-bidi-font-weight: normal;"><span style="font-size: 12.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';">Background: </span></strong><span style="font-size: 12.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';">To gain insight into the role and relevance of inflammatory and immunological markers in the comprehensive assessment of a patient’s immune response to surgical procedures. This<s> </s>study focused on investigating preoperative and postoperative serum levels dynamics of SAA, CRP, and <a name="_Hlk190895112"></a>proportion of <a name="_Hlk191246440"></a><span style="mso-bookmark: _Hlk190895112;">HLA-DR<sup>+</sup>CD14<sup>+</sup></span><span style="mso-bookmark: _Hlk190895112;">monocytes, CD14<sup>+</sup> monocytes, and pro-inflammatory monocytes CD16<sup>+</sup>CD14<sup>+</sup></span> in patients who underwent heart surgery using extracorporeal circulation (on-pump). </span></p> <p class="MsoNormal" style="margin-bottom: 0in; text-align: justify; line-height: normal;"><strong style="mso-bidi-font-weight: normal;"><span style="font-size: 12.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';">Methods</span></strong><span style="font-size: 12.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';">: An observational, prospective study was conducted at the Heart Center of the Clinical Center of the University of Sarajevo on 53 patients divided into 3 age groups: 50 – 59, 60 – 69, and 70 – 80. The serum levels of CRP and SAA were quantitatively determined by immunonephelometry. At the same time, flow cytometry technology was applied to measure the proportion of CD14<sup>+</sup> monocytes, HLA-DR<sup>+</sup>CD14<sup>+</sup>monocytes, and pro-inflammatory CD16<sup>+</sup>CD14<sup>+</sup> monocytes.</span></p> <p class="MsoNormal" style="margin-bottom: 0in; text-align: justify; line-height: normal;"><strong style="mso-bidi-font-weight: normal;"><span style="font-size: 12.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';">Results:</span></strong><span style="font-size: 12.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';"> Measured values of CRP, SAA, proportion of monocytes CD14<sup>+</sup>, and proportion of pro-inflammatory monocytes CD16<sup>+</sup>CD14<sup>+</sup> are significantly increased postoperatively compared to the preoperative values (p<0.05). The proportion of HLA-DR<sup>+</sup>CD14<sup>+</sup> monocytes is lower postoperatively compared to preoperative values (p<0.001). Furthermore, there are no significant gender differences in the preoperative or postoperative parameters (p>0.05), with the notable exception of the preoperative proportion of CD14<sup>+</sup>monocytes (p<0.05).<span style="mso-spacerun: yes;"> </span>The analysis of age-related differences indicates no significant changes in the observed preoperative and postoperative parameters among the defined age groups (p>0.05).</span></p> <p class="MsoNormal" style="margin-bottom: 0in; text-align: justify; line-height: normal;"><strong style="mso-bidi-font-weight: normal;"><span style="font-size: 12.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';">Conclusion</span></strong><span style="font-size: 12.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';">: Early monitoring of inflammatory and immunological markers in the postoperative phase could be valuable for healthcare professionals to implement prompt interventions to mitigate negative outcomes.</span></p>2025-05-27T00:00:00+02:00Copyright (c) 2025 Selma Mutevelić, Lejla Bajramović-Omeragić, Merima Šehić, Sumejja Baljević-Spahić, Belma Pehlivanović Kelle, Ermin Begović, Berina Hasanefendić, Ermina Mujičić, Marina Delić-Šarac, Drago Batinićhttps://aseestant.ceon.rs/index.php/jomb/article/view/58564Six Sigma-Based Quality Assessment of Biochemical Analytes: A Comparative Analysis of Clinical Laboratory Improvement Amendments 1988 and 2024 Standards2025-11-02T16:34:51+01:00Mert Üğemertuge6@gmail.comSaliha Aksunsalihaaksun@yahoo.com<p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; line-height: 200%;"><strong><span style="font-size: 12.0pt; line-height: 200%; font-family: 'Arial','sans-serif';">Background: </span></strong><span style="font-size: 12pt; line-height: 200%; font-family: Arial, 'sans-serif';">Laboratories have a responsibility to produce accurate and reliable results to ensure patient safety and meet quality standards. Within the Six Sigma quality management framework, different approaches may emerge depending on the total allowable error </span><span style="font-size: 12.0pt; line-height: 200%; font-family: 'Arial','sans-serif';">(TEa) limits defined by various standards. This study aimed to compare analyte sigma levels using CLIA 1988 and CLIA 2024 criteria, determine appropriate quality control procedures based on Westgard multirules, and identify potential sources of error using the Quality Goal Index.</span></p> <p style="text-align: justify; text-justify: inter-ideograph; line-height: 200%;"><strong><span style="font-family: 'Arial','sans-serif';">Methods: </span></strong><span style="font-family: 'Arial','sans-serif';">Sigma values for 17 biochemical analytes were calculated based on internal and external quality control data using the formula (TEa – bias)/CV. The Quality Goal Index (QGI) was determined using the formula bias/(1.5×CV). All analytes were evaluated at the Karabuk Public Health Laboratory between November 2024 and March 2025.</span></p> <p style="text-align: justify; text-justify: inter-ideograph; line-height: 200%;"><strong><span style="font-family: 'Arial','sans-serif';">Results: </span></strong><span style="font-family: 'Arial','sans-serif';">Amylase (Levels 1 and 2), total bilirubin (Level 1), high-density lipoprotein cholesterol (Levels 1 and 2), creatine kinase (Levels 1 and 2), and lactate dehydrogenase (Levels 1 and 2) demonstrated world-class sigma performance according to both CLIA 1988 and CLIA 2024 standards. However, a decline in sigma values was observed when calculated using the more stringent CLIA 2024 limits.</span></p> <p><strong><span style="font-size: 12.0pt; line-height: 115%; font-family: 'Arial','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: TR; mso-fareast-language: TR; mso-bidi-language: AR-SA;">Conclusions: </span></strong><span style="font-size: 12.0pt; line-height: 115%; font-family: 'Arial','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: TR; mso-fareast-language: TR; mso-bidi-language: AR-SA; mso-bidi-font-weight: bold;">The comparison of CLIA 1988 and CLIA 2024 standards demonstrated that stricter TEa limits can significantly impact sigma performance. While some analytes retained world-class performance, others showed a notable decline, requiring enhanced quality control measures. These findings emphasize the need for laboratories to periodically reassess test performance in light of evolving regulatory standards to ensure continued analytical reliability and patient safety.</span></p>2025-06-05T00:00:00+02:00Copyright (c) 2025 Mert Üğe, Saliha Aksunhttps://aseestant.ceon.rs/index.php/jomb/article/view/58168Causal effects of inflammatory cytokines on hemangioma mediated by blood metabolites: a two-step Mendelian randomization study2025-11-02T15:27:09+01:00Fan Yumedyufan@163.comYuanhe Youyouyuanhe1@163.comZhiyang Zhaozzy19980205@163.comZhuowei Tiantianomfs@163.comYanan Wangyan.an.wang@sjtu.edu.cnMeng Xiaoxiaomeng70001@126.comZhong Duduzhongd987@163.com<p class="MsoNormal" style="margin: 0cm; text-align: justify; font-size: 10.5pt; font-family: DengXian; line-height: 21px;"><strong><span lang="EN-US" style="font-size: 12pt; line-height: 24px; font-family: 'Times New Roman', serif;">Background:</span></strong><span lang="EN-US" style="font-size: 12pt; line-height: 24px; font-family: 'Times New Roman', serif;"> Hemangioma is the most prevalent infantile vascular tumor. The state of inflammation and metabolism may contribute to the occurrence and development of hemangioma, but their causal relationships have not been clearly elucidated. In this study, via Mendelian randomization (MR) analysis, we aimed to investigate the causal effect of inflammatory cytokines and blood metabolites on hemangioma, and to explore the potential mediating role of metabolites.</span></p> <p class="MsoNormal" style="margin: 0cm; text-align: justify; font-size: 10.5pt; font-family: DengXian; line-height: 21px;"><strong><span lang="EN-US" style="font-size: 12pt; line-height: 24px; font-family: 'Times New Roman', serif;">Methods: </span></strong><span lang="EN-US" style="font-size: 12pt; line-height: 24px; font-family: 'Times New Roman', serif;">Applying large-scale genome-wide association studies (GWAS) dataset, we applied two-sample MR to infer causal relationships among 91 inflammatory cytokines, 1091 blood metabolites and 309 metabolite ratios</span><span style="font-size: 12pt; line-height: 24px; font-family: 宋体;">,</span><span lang="EN-US" style="font-size: 12pt; line-height: 24px; font-family: 'Times New Roman', serif;">and hemangioma. In addition, a two-step MR was used to assess the potential mediating role of metabolites. Functional enrichment was also performed to explore the biological pathways involved.</span></p> <p class="MsoNormal" style="margin: 0cm; text-align: justify; font-size: 10.5pt; font-family: DengXian; line-height: 21px;"><strong><span lang="EN-US" style="font-size: 12pt; line-height: 24px; font-family: 'Times New Roman', serif;">Results: </span></strong><span lang="EN-US" style="font-size: 12pt; line-height: 24px; font-family: 'Times New Roman', serif;">9 cytokines exhibited significant causal effects on hemangioma. Cytokines such as CCL20, IFN-γ, Eotaxin and TRANCE were associated with an increased risk, while IL12B, CXCL11, TGF-α, OSM and IL17A were inversely associated. Additionally, 52 blood metabolites and metabolite-ratios were discovered to have causal effects on hemangioma. 18 metabolites and metabolite-ratios were associated with an elevated risk of hemangioma, whereas 34 metabolites and metabolite-ratios appeared to be protective factors. Mediation analysis further identified specific metabolites, such as Gamma-glutamylvaline, as mediators in cytokine-hemangioma pathways, suggesting that they might modulate cytokine-driven tumorigenesis.</span></p> <p class="MsoNormal" style="margin: 0cm; text-align: justify; font-size: 10.5pt; font-family: DengXian; line-height: 21px;"><strong><span lang="EN-US" style="font-size: 12pt; line-height: 24px; font-family: 'Times New Roman', serif;">Conclusion: </span></strong><span lang="EN-US" style="font-size: 12pt; line-height: 24px; font-family: 'Times New Roman', serif;">As the first MR study focused on hemangioma, we identified key cytokines and metabolites which might exert a causal effect on hemangioma, with several metabolites functioning as intermediators in cytokine-induced tumorigenesis process. The complex interaction between inflammation and metabolism in hemangioma was revealed, laying a foundation for future studies to explore potential targeted treatments.</span></p>2025-06-07T00:00:00+02:00Copyright (c) 2025 Fan Yu, Yuanhe You, Zhiyang Zhao, Zhuowei Tian, Yanan Wang, Meng Xiao, Zhong Duhttps://aseestant.ceon.rs/index.php/jomb/article/view/58742Correlation analysis of inflammatory chemokine CXCL8 and lymphoid axillary lymph node metastasis in breast cancer2025-11-02T16:37:23+01:00Ceng Lilicengxz@sina.comJinxiang Houhoujinxiang123@163.com<p>Background: In this study, we analyzed the relationship between serumchemokine CXC ligand 8 (CXCL8) and breast cancer (BC) and the predictive effect on axillary lymph node metastasis.</p> <p>Methods: 121 BC patients and 104 healthy controls were included, and serum CXCL8 was detected by ELISA to compare the differences in the levels of CXCL8 and tumor markers in the two study groups. Pathological examinations revealed that 36 of the patients had axillary lymph node metastasis. To further evaluate the diagnostic value, the ROC curve was employed to analyze the ability of CXCL8, tumor marker and combined color Doppler ultrasound blood flow richness grade (Adler grade) to assess axillary lymph node metastasis in BC patients.</p> <p>Results: Serum CXCL8 CEA, CA153, and CA27.29 were higher in BC patients than in controls (P < 0.05). Patients with lymph node metastasis had higher levels of CXCL8 CEA, CA153, and CA27.29 (P < 0.05). The AUC of CXCL8+tumor markers+Adler grade for the diagnosis of lymph node metastasis was 0.903 (95% CI: 0.850-0.957), with a sensitivity of 86.11% and a specificity of 82.35% (P < 0.001).</p> <p>Conclusion: High expression of CXCL8 is closely associated with BC lymph node metastasis.</p>2025-06-13T00:00:00+02:00Copyright (c) 2025 Ceng Li, Jinxiang Houhttps://aseestant.ceon.rs/index.php/jomb/article/view/53123. Changes in serum cholyglycine and prealbumin levels, glutamyl transpetidase , and Alpha fetoprotein after Transcatheter Arterial Chemoembolization Combined with Microwave Ablation of Liver Cancer 2025-11-02T15:27:09+01:00 Kang Chen3252373551@163.comChaojie Zhang53264359457w@163.comFeihu Sun451364918451s@163.comLei Sun82451857253e2@163.comChen Fan252ttey54574d@163.comWei-Dong WangWdoc20251@163.com<p class="MsoNormal" style="layout-grid-mode: char; mso-layout-grid-align: none;"><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';">Introduction: </span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">It aimed t</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';">o </span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">assess</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';"> the clinical </span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">outcome</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';"> of transcatheter arterial chemoembolization (TACE) and its combination with microwave ablation (MWA) in middle or advanced primary liver cancer(PLC), and to analyze the causes complications. Material and Method: According to the treatment methods, 100 patients with middle or advanced PLC were divided into TACE group (TACE</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">G</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';">) and TACE+MWA group (combination </span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">group, CG</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';">) (50 cases in each). The TACEG was treated with TACE alone, and the CG </span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">adopted</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';"> TACE combined with MWA. The quality of life (</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">QoL</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';">)SF-36 score, serum liver function index, </span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">response</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';">, 1-year overall survival (<a name="_Hlk163510301"></a>OS) rate</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">,</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';"> and complication rate were observed before and following remedy. Result: As against the TACEG, following remedy</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">,</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';"> the CG had a higher SF-36 score</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">,o</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';">bjective relief rate (ORR) (32% vs 50%)</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">,</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';"> disease control rate (DCR)(82% vs 90%)</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">, and</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';"> 1-year OS (60% vs 84%) and</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;"> a </span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';">lower 1-year complication rate (34% vs 16%)</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">;</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';">Following remedy</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">, a</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';">s against the TACEG, serum cholyglycine (CG) and prealbumin (PAB) levels were higher</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">, and</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';"> the levels of total bilirubin (TBil), direct bilirubin (DBil), alanine aminotransferase(ALT), aspartate aminotransferase (A</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">S</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';">T), alkaline phosphatase (ALP), glutamyltranspetidase (GGT)</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">,</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';"> and Alpha fetoprotein (AFP) were lower in the CG (all <em>P</em><0.05). Conclusion: TACE combined with MWA is effective and safe in middle or advanced PLC, and can markedly improve liver function and postoperative survival rate(</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif;">SR</span><span style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';">).</span></p>2025-07-05T00:00:00+02:00Copyright (c) 2025 Wei-Dong Wanghttps://aseestant.ceon.rs/index.php/jomb/article/view/54717To study the correlation between blood lactate level and neonatal hyperbilirubinemia and to predict the severity of NHB in neonates2025-11-02T16:39:01+01:00Gangqiang Zhanggangqiang1234@outlook.comKun Shaoshaokun1996@126.comYun-heng Zhouhongniwan@aliyun.com<p>Objective: To study the correlation between blood lactate level and hyperbilirubinemia in neonates and to analyze the predictive value of blood lactate level for the severity of NHB in neonates. </p> <p>Methods: A total of 123 children diagnosed with Neonatal hyperbilirubinemia (NHB) admitted to the obstetrics department from October 2021 to October 2022 were selected as the NHB group, and according to the severity of the disease, they were divided into mild, moderate, and severe. Fifty healthy neonates born in the department of obstetrics were selected as the control group. The levels of glucose-6-phosphate dehydrogenase (G6PD), creatine kinase isoenzyme (CK-MB), β2-microglobulin (β2-MG), aspartate aminotransferase (AST), blood lactic acid and total bilirubin in serum were compared. Pearson correlation analysis was used to analyze the correlation between blood lactate level and bilirubin level, and the ROC curve was used to determine the predictive value of blood lactate level for the severity of NHB in neonates. </p> <p>Results: The NHB group had significantly higher levels of AST, CK-MB, β2-MG, blood lactic acid, and total bilirubin than the NHB group (P < 0.05). G6PD level was significantly lower (P < 0.05). According to Pearson, blood lactic acid level was positively correlated with total bilirubin level (r = 0.604, P < 0.001). The ROC curve showed that the AUC of blood lactic acid level in predicting the severity of NHB was 0.873, which was higher than that of total bilirubin alone (P < 0.05).</p> <p>Conclusions: Neonates with NHB have higher serum levels of AST, CK-MB, β2-MG, blood lactate, and total bilirubin, while lower G6PD levels. The serum level of blood lactate is positively correlated with the total bilirubin level, which can be used to observe the severity of NHB in neonates.</p>2025-06-16T00:00:00+02:00Copyright (c) 2025 Gangqiang Zhang, Kun Shao, Yun-heng Zhouhttps://aseestant.ceon.rs/index.php/jomb/article/view/59085Correlation of Serum sIL-2R, VEGF, and ES with Estrogen Levels in Papillary Thyroid Carcinoma Patients and Their Predictive Value for Postoperative Recurrence2025-11-02T16:39:50+01:00Yan Guogy12345605279@163.comXin Ci13166985279@163.comShaoyu Han313834385@qq.comJianli Cui1439471329@qq.com<p class="MsoNormal"><strong><span style="font-family: 'Times New Roman'; font-size: 12pt;">Objective: </span></strong><span style="mso-spacerun: 'yes'; font-family: 'Times New Roman'; mso-fareast-font-family: 宋体; font-size: 12.0000pt; mso-font-kerning: 1.0000pt;">To explore the correlation of serum soluble interleukin-2 receptor (sIL-2R), vascular endothelial growth factor (VEGF), and endostatin (ES) with estrogen levels in papillary thyroid carcinoma (PTC) patients, and to assess the predictive efficacy of these biomarkers for PTC diagnosis and postoperative recurrence.</span></p> <p class="MsoNormal"><strong><span style="font-family: 'Times New Roman'; font-size: 12pt;">Methods: </span></strong><span style="mso-spacerun: 'yes'; font-family: 'Times New Roman'; mso-fareast-font-family: 宋体; font-size: 12.0000pt; mso-font-kerning: 1.0000pt;">From March 2023 to March 2024, 132 newly diagnosed PTC patients and 128 healthy controls were enrolled. Serum sIL-2R, VEGF, and ES levels were quantified using enzyme-linked immunosorbent assay (ELISA), while estrogen levels (estrone [E1], estradiol [E2], estriol [E3]) were measured via chemiluminescent immunoassay. Patients were followed postoperatively for one year to monitor recurrence events, including local recurrence, lymph node metastasis, and distant metastasis. The diagnostic performance of the combined model was evaluated using receiver operating characteristic (ROC) curve analysis, and Pearson correlation analysis was conducted to examine the relationship between biomarkers and estrogen levels.</span></p> <p class="MsoNormal"><strong><span style="font-family: 'Times New Roman'; font-size: 12pt;">Results: </span></strong><span style="mso-spacerun: 'yes'; font-family: 'Times New Roman'; mso-fareast-font-family: 宋体; font-size: 12.0000pt; mso-font-kerning: 1.0000pt;">Compared to controls, PTC patients exhibited significantly elevated serum sIL-2R, VEGF, and ES levels (P<0.05). The combined detection of these biomarkers demonstrated a sensitivity of 80.30% and specificity of 78.91% (AUC=0.8526) for PTC diagnosis. Additionally, E1 and E2 levels were significantly higher in PTC patients (P<0.05) and showed positive correlations with sIL-2R, VEGF, and ES (P<0.05), whereas E3 levels changed insignificantly (P>0.05). Recurrent patients had significantly higher sIL-2R, VEGF, and ES levels than non-recurrent patients (P<0.05). The combined predictive model for recurrence achieved a sensitivity of 96.88% and specificity of 61.00% (AUC=0.8494).</span></p> <p class="MsoNormal"><strong><span style="font-family: 'Times New Roman'; font-size: 12pt;">Conclusion:</span></strong><span style="mso-spacerun: 'yes'; font-family: 'Times New Roman'; mso-fareast-font-family: 宋体; font-size: 12.0000pt; mso-font-kerning: 1.0000pt;"> Elevated serum sIL-2R, VEGF, and ES levels in PTC patients indicate that their combined assessment may serve as a sensitive and specific tool for PTC diagnosis and postoperative recurrence risk stratification.</span></p>2025-06-17T00:00:00+02:00Copyright (c) 2025 Yan Guo, Xin Ci, Shaoyu Han, Jianli Cuihttps://aseestant.ceon.rs/index.php/jomb/article/view/57965The clinical value of inflammatory factors in evaluating the prognosis of patients with acute myeloid leukemia2025-11-19T04:10:45+01:00Jianghuizi LiLijianghuizi0204@163.comFeng Liurywq291@163.comWen Wuwuwen413@sohu.com<p class="MsoNormal" style="line-height: 150%;"><strong style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif;">Background: </span></strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-bidi-font-weight: bold;">To assess the importance of inflammatory factors in predicting outcomes in individuals diagnosed with acute myeloid leukemia.</span></p> <p class="MsoNormal" style="line-height: 150%;"><strong style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif;">Methods: </span></strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif; color: black; mso-themecolor: text1; mso-bidi-font-weight: bold;">Between July 2017 and <span style="mso-spacerun: yes;"> </span>December 2019, a total of 100 patients with a recent diagnosis of acute myeloid leukemia (AML) were recruited from the Hematology Department of our hospital’s Cancer Center and assigned to the AML group. Additionally, 60 individuals with no underlying health conditions who underwent standard medical checkups during the same period were selected as the control group. Serum levels of IL-2, IL-4, IL-17A, TNF-α, IFN-γ, and LIF were measured through ELISA. All participants in the AML group were followed up for three years. </span><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-bidi-font-weight: bold;">Based on the European Leukemia Network (ELN) genetic risk stratification criteria, patients were categorized into favorable, intermediate, and adverse prognosis subgroups. Inflammatory marker profiles were then compared among these subgroups. </span></p> <p class="MsoNormal" style="line-height: 150%;"><strong style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif;">Results: </span></strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif; color: black; mso-themecolor: text1; mso-bidi-font-weight: bold;">Compared to healthy individuals, the AML group presented significantly increased serum concentrations of IL-4, IL-17A, and TNF-α, while levels of IL-2, IFN-γ, and LIF were significantly decreased (P < 0.05). Upon stratifying patients by prognostic classification, those in the favorable and intermediate prognosis categories exhibited notably lower IL-4, IL-17A, and TNF-α levels relative to the poor prognosis group (all P < 0.05). In contrast, levels of IL-2, IFN-γ, and LIF were notably elevated in the subgroup with favorable prognostic profiles (all P < 0.05). Additional analysis of cytokine expression indicated that increased levels of IL-4, IL-17A, and TNF-α were linked to worse 3-year survival performance (P < 0.05). Conversely, higher expression of IL-2, IFN-γ, and LIF was significantly associated with better long-term survival outcomes relative to patients with reduced expression levels (P < 0.05).</span></p> <p class="MsoNormal" style="line-height: 150%;"><strong style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif;">Conclusion:</span></strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif;"> The abnormal levels of IL-4, IL-17A, TNF-a, IFNγ and LIF in patients with acute myeloid leukemia are increased, while the abnormal levels of IL-2, IFNγ and LIF are decreased, which has certain guiding effect on prognosis assessment and can be used as auxiliary indicators for prognosis assessment of AML.</span></p>2025-06-07T00:00:00+02:00Copyright (c) 2025 Jianghuizi Li, Feng Liu, Wen Wuhttps://aseestant.ceon.rs/index.php/jomb/article/view/58020Investigating the Causal Association Between Plasma Lipids and the Risk of Squamous Cervical Cancer: A Two-Sample Mendelian Randomization Study2025-11-02T15:27:10+01:00Yuemei Cuicuiyuemei5555@163.comYa Liljybalance@163.comJing Na121544445@qq.comJunling Luljldy2y@163.comXinyou Wang77xinai@163.comShichao Hanhscsuperman@126.comJun Wangkfwb84@163.com<p class="MsoNormal" style="line-height: 150%; layout-grid-mode: char; mso-layout-grid-align: none;"><strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: 宋体; mso-font-kerning: 18.0pt;">Purpose:</span></strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: 宋体; mso-font-kerning: 18.0pt; mso-bidi-font-weight: bold;"> This study aimed to investigate the causal relationship between plasma lipid levels—total cholesterol (TC), triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C)—and the risk of squamous cervical cancer (SCC) using Mendelian Randomization (MR).</span></p> <p class="MsoNormal" style="line-height: 150%; layout-grid-mode: char; mso-layout-grid-align: none;"><strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: 宋体; mso-font-kerning: 18.0pt;">Materials and Method:</span></strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: 宋体; mso-font-kerning: 18.0pt; mso-bidi-font-weight: bold;"> Genome-wide association study (GWAS) data for plasma lipid traits were obtained from the Global Lipids Genetics Consortium (GLGC), and SCC outcome data were sourced from the FinnGen consortium. The primary analysis was conducted using the inverse variance weighted (IVW) method, supported by MR-Egger regression, weighted median, and weighted mode approaches. Sensitivity analyses were performed to assess the robustness of the results, and the Steiger test was used to evaluate the directionality of the associations.</span></p> <p class="MsoNormal" style="line-height: 150%; layout-grid-mode: char; mso-layout-grid-align: none;"><strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: 宋体; mso-font-kerning: 18.0pt;">Results:</span></strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: 宋体; mso-font-kerning: 18.0pt; mso-bidi-font-weight: bold;"> The IVW analysis revealed that higher plasma levels of TC (OR: 1.777; 95% CI: 1.118–2.825; p = 0.015) and LDL-C (OR: 1.674; 95% CI: 1.013–2.767; p = 0.044) were associated with an increased risk of SCC. No significant associations were found between TGs (OR: 0.644; 95% CI: 0.343–1.212; p = 0.173) or HDL-C (OR: 1.050; 95% CI: 0.616–1.790; p = 0.857) and SCC.</span></p> <p class="MsoNormal" style="line-height: 150%; layout-grid-mode: char; mso-layout-grid-align: none;"><strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: 宋体; mso-font-kerning: 18.0pt;">Conclusions:</span></strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: 宋体; mso-font-kerning: 18.0pt; mso-bidi-font-weight: bold;"> This study provides evidence of a causal relationship between elevated plasma TC and LDL-C levels and a higher risk of SCC, highlighting a novel aspect of SCC etiology. These findings may inform further functional and clinical research in the progression of SCC.</span></p>2025-06-17T00:00:00+02:00Copyright (c) 2025 Yuemei Cui, Ya Li, Jing Na, Junling Lu, Xinyou Wang, Shichao Han, Jun Wanghttps://aseestant.ceon.rs/index.php/jomb/article/view/59108Clinical Utility of Jugular Venous Blood Gas Biomarkers for Assessing Traumatic Brain Injury Severity and Predicting ICU Stay Duration: A Biochemical and Predictive Modeling Approach2025-11-02T15:27:10+01:00Bin Qidugudashao@126.comWenjie Duduwenjie-666@163.comHe Zhangbzzhanghe101@163.comYuhui Jiang19805679570@126.comMing Zhuoqq897838588@163.comHaixia Xuhaixia710@163.com<p class="MsoNormal"><strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif;">Background: </span></strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif;">Biochemical monitoring of cerebral oxygen metabolism is essential in the management of traumatic brain injury (TBI). Jugular venous blood gas (JVBG) analysis provides real-time data reflecting cerebral biochemical states, offering a valuable window into brain oxygenation and metabolic demands. This study aimed to evaluate JVBG biochemical markers as indicators of TBI severity and as predictors of prolonged intensive care unit (ICU) stay, emphasizing their integration into machine learning models for clinical utility.</span></p> <p class="MsoNormal"><strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif;">Methods:</span></strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif;"> A retrospective analysis was conducted on 100 ICU-admitted TBI patients. Serial measurements of JVBG parameters—jugular venous oxygen saturation (SjvO₂), partial pressure of oxygen (PjO₂), arteriovenous oxygen difference (AVDO₂), and oxygen content difference (AVDL)—were performed over five days. Spearman correlation and random forest algorithms were employed to assess relationships between JVBG biomarkers, clinical severity (via Glasgow Coma Scale), and ICU duration.</span></p> <p class="MsoNormal"><strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif;">Results:</span></strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif;"> Patients with more severe TBI exhibited significantly reduced SjvO₂ and PjO₂, and elevated AVDO₂ and AVDL (p < 0.001). Strong correlations were found between JVBG markers and clinical severity scores. A multivariable prediction model incorporating age, SaO₂, and PaCO₂ at one day post-admission yielded excellent predictive performance for prolonged ICU stay (AUC = 0.974; sensitivity = 100%; specificity = 94.8%).</span></p> <p class="MsoNormal"><strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif;">Conclusion:</span></strong><span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif;"> JVBG biomarkers serve as clinically informative biochemical indicators for assessing TBI severity and forecasting ICU duration. Their integration into predictive algorithms may enhance precision in neurocritical care and support biochemical decision-making in intensive care settings.</span></p>2025-07-07T00:00:00+02:00Copyright (c) 2025 Bin Qi, Wenjie Du, He Zhang, Yuhui Jiang, Ming Zhuo, Haixia Xuhttps://aseestant.ceon.rs/index.php/jomb/article/view/54237. Prognostic value of serum IL-2, IFN-γ, TNF-α, IL-6, and IL-8, IL-10 in elderly Patients underwent Thoracotomy 2025-11-02T16:36:35+01:00Jia Chenprofessor.medicalli1@gmail.comLifeng MengLifengmeng25@163.com<p class="MsoNormal" style="line-height: 150%;"><strong><span style="mso-bidi-font-size: 10.5pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: SimSun; color: black; mso-themecolor: text1;">Objective:</span></strong><span style="mso-bidi-font-size: 10.5pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: SimSun; color: black; mso-themecolor: text1;"> To investigate the effect of different fluid therapy on TH1 and TH2 cytokines <span style="mso-spacerun: yes;"> </span>( IL-2, IFN-γ, TNF-α, IL-6, and IL-8 ,<span style="mso-spacerun: yes;"> </span>IL-10 ) during perioperative period of thoracotomy in elderly patients. </span></p> <p class="MsoNormal" style="line-height: 150%;"><strong><span style="mso-bidi-font-size: 10.5pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: SimSun; color: black; mso-themecolor: text1;">Methods:</span></strong><span style="mso-bidi-font-size: 10.5pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: SimSun; color: black; mso-themecolor: text1;">A total of 60 elderly patients who underwent thoracotomy from January 2022 to April 2024 were divided into the control group (CG) and the observation group (OG), with 30 cases in each group. The CG received routine fluid management, while the OG received goal-directed fluid management. The postoperative recovery status, fluid intake and output, hemodynamic indexes, TH1 and TH2 cytokine levels were compared between both groups. </span></p> <p class="MsoNormal" style="line-height: 150%;"><strong><span style="mso-bidi-font-size: 10.5pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: SimSun; color: black; mso-themecolor: text1;">Results:</span></strong><span style="mso-bidi-font-size: 10.5pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: SimSun; color: black; mso-themecolor: text1;"> The postoperative extubation time, drainage time, ICU stayand hospitalization time in the OG were reduced than those in the CG (<em>P</em><0.05). The urine volume, crystalloid volume, colloid volume and total volume of fluid in the OG werereduced than those in the CG (<em>P</em><0.05). At 1 h after surgery (T2), the HR and MAP levels of the two groups were reduced than those before surgery (T1) (<em>P</em><0.05); at the end of surgery (T3), the HR and MAP of the CG were raised than those at T1 (<em>P</em><0.05); at T2, the HR and MAP levels in the OG were raised than those in the CG (<em>P</em><0.05); at T3, the HR and MAP levels in the OG were reduced than those in the CG (<em>P</em><0.05). 1 day after operation, the levels ofIL-2, IFN-γ, TNF-α, IL-6, and IL-8 were raised than those before surgery, (<em>P</em><0.05), and the levels of IL-10 wasreduced than those before treatment (<em>P</em><0.05).</span></p> <p class="MsoNormal" style="line-height: 150%;"><strong><span style="mso-bidi-font-size: 10.5pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: SimSun; color: black; mso-themecolor: text1;">Conclusion:</span></strong><span style="mso-bidi-font-size: 10.5pt; line-height: 150%; font-family: 'Times New Roman',serif; mso-fareast-font-family: SimSun; color: black; mso-themecolor: text1;"> Perioperative goal-directed fluid therapy for elderly patients with thoracotomy is beneficial to maintain perioperative hemodynamic stability, improve serum levels of TH1 and TH2 cytokines, reduce the body's inflammatory response, and facilitate early postoperative recovery. </span></p>2025-06-11T00:00:00+02:00Copyright (c) 2025 Ling Li